The race of patients with ADPKD affects waitlist experience, allograft quality, and post-transplant outcomes, a study found. A study of real-world data found that tolvaptan reduced long-term kidney function decline in ADPKD. This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD). Novartis will acquire Regulus Therapeutics, developer of ADPKD therapeutic candidate farabursen, a novel oligonucleotide. Lupin's generic tolvaptan tablets are now FDA-approved for treating autosomal dominant polycystic kidney disease (ADPKD). A study examined the effects of SGLT2i on eGFR slope in patients with autosomal dominant polycystic kidney disease. KDIGO has published its first guideline on the evaluation, management, and treatment of ADPKD. A study examined the effects of adding dapagliflozin to treatment with tolvaptan in patients with ADPKD. A study examined whether serum phosphate levels could predict kidney outcomes in patients with ADPKD. An exploratory pilot study aimed to identify and evaluate potential proinflammatory biomarkers in patients with ADPKD. RGLS8429 increases urinary PC1 and PC2 proteins, which may help reduce height-adjusted total kidney volume in ADPKD. Could pravastatin slow the rate of increase in height-adjusted total kidney volume in adults with ADPKD? Researchers assessed the safety and efficacy of bardoxolone methyl (BARD) in patients with ADPKD. Recent research reveals tolvaptan’s role in reducing hemodialysis initiation risk in ADPKD, A study examined physician confidence and barriers to prescription of tolvaptan for the management of ADPKD. A study investigated whether treatment with difelikefalin and tolvaptan can protect against worsening of late-stage PKD. ESSENTIAL assessed the safety and effectiveness of tolvaptan among patients in Korea with ADPKD and CKD stages 1 to 3. Tolvaptan increased serum sodium without causing sodium overcorrection in syndrome of inappropriate antidiuresis. A post hoc analysis of TEMPO 3:4 results examined longer-term effects of tolvaptan on TKV and eGFR in patients with ADPKD. Data regarding mortality specific to patients with autosomal dominant polycystic kidney disease (ADPKD) are limited.